Dr. Tomasson Reports Early Data from MagentisMM-20

Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma. In a small study, all 12 patients responded, with manageable side effects. This combination may help advanced cases, according to the study investigators. Dr. Tomasson highlights ongoing research into bispecific antibodies, chimeric antigen receptor T-cell therapy, and the path toward a cure for patients with multiple myeloma.